InsiderTrades.com logo

KTTA Insider Trading

Insider Ownership Percentage: 2.70%
Insider Buying (Last 12 Months): $149,999.25
Insider Selling (Last 12 Months): $787.20

Pasithea Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Pasithea Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Pasithea Therapeutics Share Price & Price History

Current Price: $1.16
Price Change: ▼ Price Decrease of -0.01 (-0.85%)
As of 12/4/2025 05:00 PM ET

This chart shows the closing price history over time for KTTA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Pasithea Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/28/2025Lawrence SteinmanDirectorBuy133,333$0.75$99,999.75199,691View SEC Filing Icon  
11/28/2025Simon DumesnilDirectorBuy33,333$0.75$24,999.7535,833View SEC Filing Icon  
11/28/2025Tiago MarquesCEOBuy33,333$0.75$24,999.7573,334View SEC Filing Icon  
5/12/2025Tiago MarquesCEOSell960$0.82$787.2040,001View SEC Filing Icon  
6/2/2023Lawrence SteinmanDirectorBuy1,500$8.60$12,900.0066,358View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Pasithea Therapeutics (NASDAQ:KTTA)

23.92% of Pasithea Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at KTTA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Pasithea Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/17/2025Citadel Advisors LLC67,341$48K0.0%+43.7%0.905%Search for SEC Filing on Google Icon
11/14/2025Two Sigma Investments LP35,760$26K0.0%N/A0.480%Search for SEC Filing on Google Icon
11/5/2025AdvisorShares Investments LLC257,696$0.19M0.0%+33.1%3.462%Search for SEC Filing on Google Icon
8/4/2025AdvisorShares Investments LLC193,547$0.14M0.0%+261.5%2.601%Search for SEC Filing on Google Icon
2/10/2023K2 Principal Fund L.P.282,437$0.18M0.0%-42.6%0.966%Search for SEC Filing on Google Icon
5/12/2022Mark Sheptoff Financial Planning LLC48,000$62K0.0%N/A0.210%Search for SEC Filing on Google Icon
2/11/2022K2 Principal Fund L.P.550,000$0.97M0.1%N/A4.164%Search for SEC Filing on Google Icon
11/16/2021Two Sigma Securities LLC10,440$32K0.0%N/A0.080%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Pasithea Therapeutics logo
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Read More on Pasithea Therapeutics

Today's Range

Now: $1.16
Low: $1.11
High: $1.21

50 Day Range

MA: $0.77
Low: $0.29
High: $1.36

52 Week Range

Now: $1.16
Low: $0.28
High: $3.85

Volume

1,428,797 shs

Average Volume

21,355,620 shs

Market Capitalization

$8.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.21

Who are the company insiders with the largest holdings of Pasithea Therapeutics?

Pasithea Therapeutics' top insider investors include:
  1. Lawrence Steinman (Director)
  2. Tiago Marques (CEO)
  3. Simon Dumesnil (Director)
Learn More about top insider investors at Pasithea Therapeutics.

Who are the major institutional investors of Pasithea Therapeutics?

Pasithea Therapeutics' top institutional investors include:
  1. AdvisorShares Investments LLC — 3.46%
  2. Citadel Advisors LLC — 0.90%
  3. Two Sigma Investments LP — 0.48%
Learn More about top institutional investors of Pasithea Therapeutics stock.

Which institutional investors are buying Pasithea Therapeutics stock?

Within the previous quarter, KTTA stock was bought by institutional investors including:
  1. AdvisorShares Investments LLC
  2. Two Sigma Investments LP
  3. Citadel Advisors LLC
In the last year, these company insiders have bought Pasithea Therapeutics stock:
  1. Lawrence Steinman (Director)
  2. Tiago Marques (CEO)
  3. Simon Dumesnil (Director)
Learn More investors buying Pasithea Therapeutics stock.